SCHEMBL7280595

SCHEMBL7280595

Cc1nccn1-c1nc(NCc2ccccc2)c2ccccc2n1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 7/20 0.61
PTGS1 P23219 2/20 0.61
TBXAS1 P24557 2/20 0.61
PTGS2 P35354 2/20 0.61
PDE3B Q13370 1/20 0.61
PDE3A Q14432 1/20 0.61
HRH4 Q9H3N8 1/20 0.57
RAD52 P43351 1/20 0.53
KMT2A Q03164 3/20 0.52
KDM4E B2RXH2 2/20 0.52
MAPT P10636 2/20 0.52
NPSR1 Q6W5P4 2/20 0.52
ALDH1A1 P00352 1/20 0.52
LMNA P02545 1/20 0.52
PKM P14618 1/20 0.52
UBE2N P61088 1/20 0.52
RCE1 Q9Y256 1/20 0.52
BCHE P06276 4/20 0.52
ACHE P22303 4/20 0.52
MAPK1 P28482 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7609413 0.82 EGFR (0.43) PDE5APTGS1TBXAS1PTGS2PDE3B
SCHEMBL5115007 0.80 PDE5A (0.43) PDE5APTGS1TBXAS1PTGS2PDE3B
SCHEMBL5123780 0.80 ICAM1 (0.57) PDE5APTGS1TBXAS1PTGS2PDE3B
SCHEMBL7604885 0.79 PDE5A (0.42) PDE5APTGS1TBXAS1PTGS2PDE3B
SCHEMBL7615097 0.79 LATS1 (0.43) PDE5APTGS1TBXAS1PTGS2PDE3B
SCHEMBL5115394 0.78 ICAM1 (0.41) PDE5APTGS1TBXAS1PTGS2PDE3B
SCHEMBL801616 0.78 HRH4 (0.38) PDE5APTGS1TBXAS1PTGS2PDE3B
SCHEMBL5116457 0.78 ALDH1A1 (0.47) KMT2AKDM4EMAPTNPSR1ALDH1A1
SCHEMBL5125398 0.78 ESR1 (0.47) PDE5APTGS1TBXAS1PTGS2PDE3B
SCHEMBL7612662 0.77 PDE5A (0.41) PDE5APTGS1TBXAS1PTGS2PDE3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0579496-B1 4-Aminoquinazoline derivatives, and their use as medicine ONO PHARMACEUTICAL CO (JP) 2001-11-14 EP claimed
EP-0579496-A1 4-Aminoquinazoline derivatives, and their use as medicine ONO PHARMACEUTICAL CO., LTD. (JP) 1994-01-19 EP claimed
US-20020025968-A1 Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives OSI PHARMACEUTICALS, INC. 2002-02-28 US disclosed
EP-0579496-B1 4-Aminoquinazoline derivatives, and their use as medicine ONO PHARMACEUTICAL CO (JP) 2001-11-14 EP disclosed
US-5439895-A Cardiovascular disorders; inhibitor of thromboxane A2 synthetase and cyclic guanosine 3',5'-monophosphate ONO PHARMACEUTICAL CO., LTD. (JP) 1995-08-08 US disclosed
US-5436233-A Nervous system disorders ONO PHARMACEUTICAL CO., LTD. (JP) 1995-07-25 US disclosed
EP-0579496-A1 4-Aminoquinazoline derivatives, and their use as medicine ONO PHARMACEUTICAL CO., LTD. (JP) 1994-01-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020025968-A1 Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives VHL, MCL1, NFATC1 PDE5A 3794/4885PTGS1 419/4885TBXAS1 977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.